267 related articles for article (PubMed ID: 25821426)
1. Amorolfine vs. ciclopirox - lacquers for the treatment of onychomycosis.
Tabara K; Szewczyk AE; Bienias W; Wojciechowska A; Pastuszka M; Oszukowska M; Kaszuba A
Postepy Dermatol Alergol; 2015 Feb; 32(1):40-5. PubMed ID: 25821426
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
Gupta AK
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
[TBL] [Abstract][Full Text] [Related]
3. A pilot, layerwise, ex vivo evaluation of the antifungal efficacy of amorolfine 5% nail lacquer vs other topical antifungal nail formulations in healthy toenails.
Ghannoum M; Long L; Kunze G; Sarkany M; Osman-Ponchet H
Mycoses; 2019 Jun; 62(6):494-501. PubMed ID: 30667544
[TBL] [Abstract][Full Text] [Related]
4. Activity of amorolfine or ciclopirox in combination with terbinafine against pathogenic fungi in onychomycosis-Results of an in vitro investigation.
Schaller M; Walker B; Nabhani S; Odon A; Riel S; Jäckel A
Mycoses; 2024 Mar; 67(3):e13710. PubMed ID: 38414346
[TBL] [Abstract][Full Text] [Related]
5. An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis.
Jaiswal A; Sharma RP; Garg AP
Indian J Dermatol Venereol Leprol; 2007; 73(6):393-6. PubMed ID: 18032857
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: A meta-analysis and systematic review.
Feng X; Xiong X; Ran Y
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28097731
[TBL] [Abstract][Full Text] [Related]
7. Visualisation of penetration of topical antifungal drug substances through mycosis-infected nails by matrix-assisted laser desorption ionisation mass spectrometry imaging.
Endringer Pinto F; Bagger C; Kunze G; Joly-Tonetti N; Thénot JP; Osman-Ponchet H; Janfelt C
Mycoses; 2020 Aug; 63(8):869-875. PubMed ID: 32406142
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis.
Schaller M; Sigurgeirsson B; Sarkany M
Mycoses; 2017 Dec; 60(12):800-807. PubMed ID: 28925059
[TBL] [Abstract][Full Text] [Related]
9. A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers.
Sidou F; Soto P
Int J Tissue React; 2004; 26(1-2):17-24. PubMed ID: 15573688
[TBL] [Abstract][Full Text] [Related]
10. Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer: A Review of Its Use in Onychomycosis.
Piraccini BM; Iorizzo M; Lencastre A; Nenoff P; Rigopoulos D
Dermatol Ther (Heidelb); 2020 Oct; 10(5):917-929. PubMed ID: 32705532
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.
Paul C; Coustou D; Lahfa M; Bulai-Livideanu C; Doss N; Mokthar I; Turki H; Nouira R; Fazaa B; Ben Osman A; Zourabichvili O; Cazeau C; Coubetergues H; Picot S; Bienvenu AL; Voisard JJ
Dermatology; 2013; 227(2):157-64. PubMed ID: 24051622
[TBL] [Abstract][Full Text] [Related]
12. The use of topical therapies to treat onychomycosis.
Gupta AK; Ryder JE; Baran R
Dermatol Clin; 2003 Jul; 21(3):481-9. PubMed ID: 12956200
[TBL] [Abstract][Full Text] [Related]
13. Development of topical therapeutics for management of onychomycosis and other nail disorders: a pharmaceutical perspective.
Elsayed MM
J Control Release; 2015 Feb; 199():132-44. PubMed ID: 25481439
[TBL] [Abstract][Full Text] [Related]
14. Ciclopirox nail lacquer solution 8% in the 21st century.
Gupta AK; Baran R
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S96-102. PubMed ID: 11051138
[TBL] [Abstract][Full Text] [Related]
15. Potential of Chemical and Physical Enhancers for Transungual Delivery of Amorolfine Hydrochloride.
Šveikauskaitė I; Pockevičius A; Briedis V
Materials (Basel); 2019 Mar; 12(7):. PubMed ID: 30925734
[TBL] [Abstract][Full Text] [Related]
16. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement.
Baran R; Sigurgeirsson B; de Berker D; Kaufmann R; Lecha M; Faergemann J; Kerrouche N; Sidou F
Br J Dermatol; 2007 Jul; 157(1):149-57. PubMed ID: 17553051
[TBL] [Abstract][Full Text] [Related]
17. Onychomycosis in children: a brief overview with treatment strategies.
Gupta AK; Skinner AR
Pediatr Dermatol; 2004; 21(1):74-9. PubMed ID: 14871333
[TBL] [Abstract][Full Text] [Related]
18. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents.
Del Rosso JQ
J Clin Aesthet Dermatol; 2014 Jul; 7(7):10-8. PubMed ID: 25053979
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of topical resin lacquer, amorolfine and oral terbinafine for treating toenail onychomycosis: a prospective, randomized, controlled, investigator-blinded, parallel-group clinical trial.
Auvinen T; Tiihonen R; Soini M; Wangel M; Sipponen A; Jokinen JJ
Br J Dermatol; 2015 Oct; 173(4):940-8. PubMed ID: 26036329
[TBL] [Abstract][Full Text] [Related]
20. Ciclopirox nail lacquer: a brush with onychomycosis.
Gupta AK
Cutis; 2001 Aug; 68(2 Suppl):13-6. PubMed ID: 11665723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
